Form 8-K - Current report:
SEC Accession No. 0001213900-25-008385
Filing Date
2025-01-30
Accepted
2025-01-30 16:15:32
Documents
15
Period of Report
2025-01-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0228911-8k_lomond.htm   iXBRL 8-K 32271
2 FORM OF AMENDMENT NO. 1 TO SUBSCRIPTION AGREEMENTS, DATED JANUARY 24, 2025 ea022891101ex10-1_lomond.htm EX-10.1 14938
  Complete submission text file 0001213900-25-008385.txt   269758

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE cik0001900520-20250124.xsd EX-101.SCH 3344
4 XBRL DEFINITION FILE cik0001900520-20250124_def.xml EX-101.DEF 26675
5 XBRL LABEL FILE cik0001900520-20250124_lab.xml EX-101.LAB 36628
6 XBRL PRESENTATION FILE cik0001900520-20250124_pre.xml EX-101.PRE 25330
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0228911-8k_lomond_htm.xml XML 4918
Mailing Address C/O LOMOND THERAPEUTICS HOLDINGS, INC. 8 THE GREEN STE 8490 DOVER DE 19901
Business Address C/O LOMOND THERAPEUTICS HOLDINGS, INC. 8 THE GREEN STE 8490 DOVER DE 19901 561 464 2841
Lomond Therapeutics Holdings, Inc. (Filer) CIK: 0001900520 (see all company filings)

EIN.: 872959575 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-56377 | Film No.: 25573931
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)